Andrx Issued Five Additional Patents.

Business Editors

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 29, 2000

ANDRX CORPORATION (Nasdaq:ADRX) today announced that, over the past month, five additional controlled-release patents have been issued in its favor by the United States Patent and Trademark Office. One of these patents relates to Andrx's Stabilized Pellet Delivery System ("SPDS") and complements another patent which issued in June of this year, two relate to Andrx's Single Composition Osmotic Tablet ("SCOT") technology, one relates to Andrx's Granulated Modulating Hydrogel System ("GMHS"), and one relates to Andrx's Delayed Pulsatile Hydrogel System ("DPHS"). SPDS technology has been applied to the Company's Abbreviated New Drug Application ("ANDA") for a bioequivalent version of Prilosec(R), which has been tentatively approved by the Food and Drug Administration ("FDA"). One of the new SCOT patents relates to the Company's formulation for a controlled-release version of metformin, which the Company intends to submit to the FDA as a New Drug Application ("NDA"), while the second SCOT patent describes a controlled-release formulation combining metformin and glipizide. Andrx is utilizing GMHS in its ANDA for Lodine(R) XL, which was submitted to the FDA earlier this year, and DPHS technology in its efforts to develop a bioequivalent version of Adalat(R) CC.

"Each of these patents signifies that Andrx scientists have made both novel and useful drug delivery advancements," said Elliot F. Hahn, Ph.D., Andrx's president. "Together with the patents previously issued, which cover eight drug delivery technologies that we developed in-house, these five patents further confirm that Andrx is continuing to make scientific advancements in its efforts to develop both branded and generic controlled-release pharmaceuticals."

Andrx is engaged in the formulation and commercialization of oral controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies. In its ANDA program, the Company is developing generic versions of selected high sales volume controlled-release brand name pharmaceuticals. In its NDA program, the Company is developing its own brand name formulations of certain existing drugs that it believes may be improved by the application of the Company's drug delivery technologies. The Company also markets and distributes pharmaceutical products manufactured by third parties and, through its Cybear, Inc. subsidiary (Nasdaq:CYBA), is developing internet-based software and applications for the healthcare industry.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.